Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 7, 2021, Robert W. Pangia notified Biogen Inc. (the "Company" or "Biogen") that he will retire from the Board of Directors (the "Board") and will not stand for reelection at the Company's 2021 annual meeting of stockholders. Mr. Pangia will remain a director of the Company until the Company's 2021 annual meeting of stockholders, scheduled for June 2, 2021. Mr. Pangia's decision to not stand for reelection was not related to any disagreement with the Company on any matter relating to its operations, policies or practices. On April 9, 2021, the Company issued a press release announcing the retirement of Mr. Pangia, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. Item 8.01 Other Events.


  On April 9, 2021, the Company issued a press release announcing the nomination
of Maria C. Freire, Ph.D. and William D. Jones to stand for election to the
Company's Board at its 2021 annual meeting of stockholders, scheduled for June
2, 2021.
A copy of the press release is attached to this Current Report on Form 8-K as
Exhibit 99.1 and is incorporated herein by reference.
Additional Information and Where to Find It
Biogen, its directors and certain of its executive officers may be deemed to be
participants in the solicitation of proxies from stockholders in connection with
the matters to be considered at Biogen's 2021 annual meeting of stockholders.
Biogen intends to file a proxy statement with the U.S. Securities and Exchange
Commission (the "SEC") in connection with such solicitation of proxies from
stockholders. STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT
WHEN IT BECOMES AVAILABLE AS IT WILL CONTAIN IMPORTANT INFORMATION. Information
regarding ownership of Biogen stock and other securities by Biogen directors and
executive officers is included in their SEC filings on Forms 3, 4 and 5, which
can be found through the Biogen website (www.biogen.com) in the section
"Investors" or through the SEC's website at www.sec.gov. Additional information
about Biogen's directors and executive officers and their interests is set forth
in Biogen's Annual Report on Form 10-K for the fiscal year ended December 31,
2020, which was filed with the SEC on February 3, 2021, and Biogen's proxy
statement for its 2020 annual meeting of stockholders, which was filed with the
SEC on April 20, 2020, and in Biogen's other SEC filings, which can be found
through Biogen's website (www.biogen.com) in the section "Investors" or through
the SEC's website at www.sec.gov. More detailed and updated information
regarding the identity of potential participants, and their direct or indirect
interests, by security holdings or otherwise, will be set forth in the proxy
statement and other materials to be filed with the SEC in connection with
Biogen's 2021 annual meeting of stockholders. Stockholders will be able to
obtain any proxy statement, any amendments or supplements to the proxy statement
and other documents filed by Biogen with the SEC for no charge at the SEC's
website at www.sec.gov. Copies will also be available at no charge at Biogen's
website at www.biogen.com.

Item 9.01 Financial Statements and Exhibits.



(d)  Exhibits
The exhibits listed below are furnished as part of this Current Report on Form
8-K.
Exhibit No.              Description
99.1                       Press Release of Biogen Inc. issued April 9, 2021
                         Cover Page Interactive Data File (embedded within the Inline XBRL
104                      document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses